CDH17 Antibody and Cell Assay Selection Guide Domain, Conformation, and Cross-Species Considerations

Cadherin-17 (CDH17) is a non-classical calcium-dependent adhesion protein predominantly expressed in the intestinal epithelium and highly upregulated in multiple gastrointestinal tumors. Due to its tumor-specific expression, CDH17 has become a promising therapeutic target. Current CDH17-targeting strategies include: Antibody-drug conjugates (ADC), Cell therapies (CAR-T/CAR-NK), Monoclonal, bispecific, or trispecific antibodies. For a comprehensive overview of CDH17 biology and ongoing clinical developments, see CDH17 Mechanisms and Drug Pipeline…

The extracellular region of CDH17 contains seven cadherin repeats (EC1–EC7). Each domain has distinct surface exposure, conformational stability, and functional relevance, which directly impact antibody binding and assay outcomes.

Best practice: Use multi-domain or segmented ECD proteins for primary antibody screening (ELISA, BLI, SPR), epitope mapping, domain preference analysis, and cross-comparison of antibody affinities.

Early domain-specific selection accelerates antibody discovery and reduces reliance on complex systems.

SKU	Product Name	Molecular Characterization
PME100801	Human CDH17 Protein, His Tag	CDH17(Gln23-Met787) 6×His tag
PME100199	Human CDH17(567-667) Protein, hFc Tag	CDH17(Ser567-Leu667) hFc(Glu99-Ala330)
PME101384	Human CDH17(567-667) Protein, mFc Tag	CDH17(Ser567-Leu667) mFc(Pro99-Lys330)
PME101562	Human CDH17(30-128) Protein, hFc Tag	CDH17(Pro30-Gln128) hFc(Glu99-Ala330)
PME101563	Human CDH17(129-244) Protein, hFc Tag	CDH17(Ser129-Pro244) hFc(Glu99-Ala330)
PME101564	Human CDH17(245-340) Protein, hFc Tag	CDH17(Val245-Cys340) hFc(Glu99-Ala330)
PME101565	Human CDH17(341-449) Protein, hFc Tag	CDH17(Pro341-Phe449) hFc(Glu99-Ala330)
PME101566	Human CDH17(450-566) Protein, hFc Tag	CDH17(Glu450-Phe566) hFc(Glu99-Ala330)
PME101567	Human CDH17(668-777) Protein, hFc Tag	CDH17(Ala668-Gly777) hFc(Glu99-Ala330)
PME101608	Human CDH17(23-128) Protein, hFc Tag	CDH17(Gln23-Gln128) hFc(Glu99-Ala330)
PME101623	Human CDH17(668-787) Protein, hFc Tag	CDH17(Ala668-Met787) hFc(Glu99-Ala330)
PME101841	Human CDH17 Protein, hFc Tag	CDH17(Gln23-Met787) hFc(Glu99-Ala330)
PME101842	Human CDH17 Protein, mFc Tag	CDH17(Gln23-Met787) mFc(Pro99-Lys330)

For Domain-Specific Protein Fragments in Therapeutic Antibody Discovery…

In antibody development, the lack of a proper “reference” can make result interpretation difficult. For CDH17, incorporating validated reference antibodies can significantly improve screening efficiency and data reliability. These products are suitable for:

• Comparing binding capabilities of new antibodies with known antibodies
• Confirming the proper setup of experimental systems (ELISA / flow cytometry)
• Serving as positive controls in functional assays

Using a positive control helps prevent false conclusions caused by experimental system issues rather than antibody performance and enhances data comparability across batches and experiments.

SKU	Product Name	Applications
BME100198	Anti-CDH17(ARB102 biosimilar) mAb	ELISA, Flow Cyt
BME100198B	Biotinylated Anti-CDH17(ARB102 biosimilar) mAb	ELISA, Flow Cyt
BME100233	Anti-CDH17(TORL-3-600 biosimilar) mAb	ELISA, Flow Cyt
BME100198P	PE-conjugated Anti-CDH17(ARB102 biosimilar) mAb	Flow Cyt
BME100233P	PE-conjugated Anti-CDH17(TORL-3-600 biosimilar) mAb	Flow Cyt
BME100262	Anti-CDH17(ADC-646-h7 biosimilar) mAb	ELISA, Flow Cyt

CDH17 is a typical membrane protein whose native conformation is fully maintained only in the cellular membrane environment. Antibodies screened solely with soluble proteins often require additional validation to confirm recognition of the natural membrane-bound form.

Live-cell flow cytometry is an effective method to assess whether an antibody truly binds to CDH17 in its native conformation on cell surfaces. Applications include:

• Validating antibody binding to membrane-expressed CDH17
• Functional studies, such as blocking or internalization assays
• Eliminating false-positive antibodies that bind soluble protein but fail to recognize the native membrane form

This strategy ensures that candidate antibodies are likely to retain activity in functional assays and provides a reliable foundation for CAR design and therapeutic antibody development.

SKU	Product Name	Applications
DMC100637	Anti-CDH17 antibody(5F5), IgG1 Chimeric mAb	WB; Flow Cyt
DMC100637B	Biotinylated Anti-CDH17 antibody(5F5), IgG1 Chimeric mAb	WB; Flow Cyt
CEL100009	Hu_CDH17 K562 Cell Line	Flow Cyt

Before entering animal studies or translational research, it is critical to evaluate an antibody’s cross-species binding capability.

• Mouse-derived CDH17 proteins: Used to determine antibody suitability for mouse models
• Monkey-derived CDH17 proteins: Support safety and PK/PD studies in non-human primates
• Combined use of cross-species and human CDH17 proteins: Helps anticipate and mitigate key risks in in vivo studies

SKU	Product Name	Molecular Characterization
PME-M100098	Mouse CDH17 Protein, His Tag	Mouse CDH17(Phe26-Met786) 6×His tag
PME-C100029	Cynomolgus CDH17 Protein, His Tag	CDH17(Lys30-Thr792) 10×His tag

Explore the role of multi-species proteins in antibody drug development >>

Rather than repeatedly testing a single product, selecting CDH17 product combinations tailored to each research stage can more efficiently advance projects to the next phase.

Research on CDH17 involves domain analysis, native conformation recognition, functional validation, and methodological standardization. By combining multi-domain ECD proteins, reference antibodies, and live-cell flow cytometry, researchers can systematically and efficiently perform antibody screening, epitope mapping, and functional validation.